Uniquity Bio Reports Positive Phase 2 Results for Solrikitug in Eosinophilic Esophagitis Treatment
Uniquity Bio, a clinical-stage drug development company, has announced positive topline data from its Phase 2 ALAMERE clinical trial for solrikitug, a treatment for eosinophilic esophagitis (EoE). Solrikitug, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), demonstrated statistically significant and clinically meaningful results across all tested doses (125 mg, 250 mg, 500 mg) at week 24. The co-primary endpoints, histologic remission rates and improvement in dysphagia symptoms, were met. Solrikitug achieved placebo-corrected histologic remission rates of 69%-76% and reduced the frequency and severity of dysphagia symptoms by 8.8-12.6 points. The drug was well tolerated with a favorable safety profile. EoE is a chronic inflammatory condition of the esophagus affecting an estimated 470,000 people in the United States, with limited treatment options. Will Kane, CEO of Uniquity, stated that these data reinforce solrikitug's high potency and potential for a best-in-class profile, with plans...